Merck says 2027 will focus on pipeline and new product launches despite recent trial wins

Merck's chief financial officer said the company views 2027 as another year of investment, emphasizing its expanding pipeline and upcoming product launches rather than short‑term margin growth.

The firm expects underlying operating expenses to rise at a mid‑ to high‑single‑digit rate, reflecting confidence in the opportunities presented by its growing portfolio.

Merck also highlighted that business development remains a key priority and that it retains financial flexibility under its investment‑grade credit rating to pursue science‑driven, value‑enhancing transactions.